Log in

Relevant bibliographies by topics / Cystic fibrosis Gene therapy / Journal articles

Journal articles on the topic 'Cystic fibrosis Gene therapy'

To see the other types of publications on this topic, follow the link: Cystic fibrosis Gene therapy.

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cystic fibrosis Gene therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Griesenbach, Uta, Jane C. Davies, and Eric Alton. "Cystic fibrosis gene therapy." Current Opinion in Pulmonary Medicine 22, no. 6 (November 2016): 602–9. http://dx.doi.org/10.1097/mcp.0000000000000327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Colledge, W. H., and M. J. Evans. "Cystic fibrosis gene therapy." British Medical Bulletin 51, no. 1 (January 1995): 82–90. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072955.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Colledge, William H. "Cystic fibrosis gene therapy." Current Opinion in Genetics & Development 4, no. 3 (June 1994): 466–71. http://dx.doi.org/10.1016/0959-437x(94)90037-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Prickett, Michelle, and Manu Jain. "Gene therapy in cystic fibrosis." Translational Research 161, no. 4 (April 2013): 255–64. http://dx.doi.org/10.1016/j.trsl.2012.12.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Colledge, WH. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1249. http://dx.doi.org/10.1016/s0140-6736(97)26017-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dodge, J. A. "Gene therapy for cystic fibrosis." Nature Medicine 1, no. 3 (March 1995): 182. http://dx.doi.org/10.1038/nm0395-182a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Armstrong, D. K., S. Cunningham, J. C. Davies, and E. W. F. Alton. "Gene therapy in cystic fibrosis." Archives of Disease in Childhood 99, no. 5 (January 24, 2014): 465–68. http://dx.doi.org/10.1136/archdischild-2012-302158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wagner, MD, PhD, John A., and Phyllis Gardner, MD. "TOWARD CYSTIC FIBROSIS GENE THERAPY." Annual Review of Medicine 48, no. 1 (February 1997): 203–16. http://dx.doi.org/10.1146/annurev.med.48.1.203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Flotte, Terence R., and Beth L. Laube. "Gene Therapy in Cystic Fibrosis." Chest 120, no. 3 (September 2001): 124S—131S. http://dx.doi.org/10.1378/chest.120.3_suppl.124s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alton, Eric, Stephen Smith, and Duncan Geddes. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1249–50. http://dx.doi.org/10.1016/s0140-6736(05)62441-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Janet E Larson, Y., Susan L. Morrow, and J. Craig Cohen. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1250. http://dx.doi.org/10.1016/s0140-6736(05)62442-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Turner, Gillian. "Gene therapy for cystic fibrosis." Lancet 349, no. 9060 (April 1997): 1250–51. http://dx.doi.org/10.1016/s0140-6736(05)62443-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Boyd, A. Christopher. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 11, no. 1 (January 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Boyd, A. Christopher. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 11, no. 2 (February 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.2.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Conese, Massimo, Sante Di Gioia, and Stefano Castellani. "Gene therapy for cystic fibrosis." Expert Opinion on Therapeutic Patents 18, no. 8 (August 2008): 929–43. http://dx.doi.org/10.1517/13543776.18.8.929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Davies, Jane C., Duncan M. Geddes, and Eric W. F. W. Alton. "Gene therapy for cystic fibrosis." Journal of Gene Medicine 3, no. 5 (2001): 409–17. http://dx.doi.org/10.1002/jgm.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bellon, G. "Cystic fibrosis (CF) gene therapy." Pediatric Pulmonology 23, S16 (April 1997): 278–79. http://dx.doi.org/10.1002/ppul.19502308144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Johnson, Larry G. "Gene Therapy for Cystic Fibrosis." Chest 107, no. 2 (February 1995): 77S—83S. http://dx.doi.org/10.1378/chest.107.2_supplement.77s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Rosenfeld, Melissa A., and Francis S. Collins. "Gene Therapy for Cystic Fibrosis." Chest 109, no. 1 (January 1996): 241–52. http://dx.doi.org/10.1378/chest.109.1.241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Coutelle, C., N. Caplen, S. Hart, C. Huxley, and R. Williamson. "Gene therapy for cystic fibrosis." Archives of Disease in Childhood 68, no. 4 (April 1, 1993): 437–40. http://dx.doi.org/10.1136/adc.68.4.437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kitson, Chris, and Eric Alton. "Gene therapy for cystic fibrosis." Expert Opinion on Investigational Drugs 9, no. 7 (July 2000): 1523–35. http://dx.doi.org/10.1517/13543784.9.7.1523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Davies, J. C., and E. W. F. W. Alton. "Gene Therapy for Cystic Fibrosis." Proceedings of the American Thoracic Society 7, no. 6 (October 28, 2010): 408–14. http://dx.doi.org/10.1513/pats.201004-029aw.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Luder, Elisabeth. "Gene Therapy for Cystic Fibrosis." Topics in Clinical Nutrition 14, no. 4 (September 1999): 22–30. http://dx.doi.org/10.1097/00008486-199909000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mueller, Christian, and Terence R. Flotte. "Gene Therapy for Cystic Fibrosis." Clinical Reviews in Allergy & Immunology 35, no. 3 (July 4, 2008): 164–78. http://dx.doi.org/10.1007/s12016-008-8080-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Alton, E. W. F. W. "Gene therapy for cystic fibrosis." Journal of Inherited Metabolic Disease 18, no. 4 (1995): 501–7. http://dx.doi.org/10.1007/bf00710061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Geddes, D. "Gene therapy for cystic fibrosis." Netherlands Journal of Medicine 46, no. 6 (June 1995): 306–12. http://dx.doi.org/10.1016/0300-2977(95)00024-h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Coutelle, Charles. "Gene therapy approaches for cystic fibrosis." Biologicals 23, no. 1 (March 1995): 21–25. http://dx.doi.org/10.1016/1045-1056(95)90006-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Brown, Matt. "Gene therapy trials for cystic fibrosis." Drug Discovery Today 7, no. 15 (August 2002): 788–89. http://dx.doi.org/10.1016/s1359-6446(02)02393-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Higgins, Christopher F., Stephen C. Hyde, and Deborah R. Gill. "Towards Gene Therapy for Cystic Fibrosis." Biochemical Society Transactions 27, no. 5 (October 1, 1999): A137. http://dx.doi.org/10.1042/bst027a137a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

ALTON, E. W. F. W. "Towards Gene Therapy For Cystic Fibrosis*." Journal of Pharmacy and Pharmacology 47, no. 5 (May 1995): 351–54. http://dx.doi.org/10.1111/j.2042-7158.1995.tb05809.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ezzell, C. "Gene Therapy for Cystic Fibrosis Patients." Science News 142, no. 24 (December 12, 1992): 405. http://dx.doi.org/10.2307/4017870.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

O'Neal, WK, and AL Beaudet. "Somatic gene therapy for cystic fibrosis." Human Molecular Genetics 3, suppl_1 (September 1, 1994): 1497–502. http://dx.doi.org/10.1093/hmg/3.suppl_1.1497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Griesenbach, Uta, Duncan M. Geddes, and Eric W. F. W. Alton. "Advances in cystic fibrosis gene therapy." Current Opinion in Pulmonary Medicine 10, no. 6 (November 2004): 542–46. http://dx.doi.org/10.1097/01.mcp.0000142102.91202.04.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Griesenbach, U., and E. W. F. W. Alton. "Moving forward: cystic fibrosis gene therapy." Human Molecular Genetics 22, R1 (August 4, 2013): R52—R58. http://dx.doi.org/10.1093/hmg/ddt372.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Parsons, DW. "Airway gene therapy and cystic fibrosis." Journal of Paediatrics and Child Health 41, no. 3 (March 2005): 94–96. http://dx.doi.org/10.1111/j.1440-1754.2005.00556.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Wilson, James. "Cystic Fibrosis: Strategies for Gene Therapy." Seminars in Respiratory and Critical Care Medicine 15, no. 05 (September 1994): 439–45. http://dx.doi.org/10.1055/s-2007-1006389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Drittanti, L., MV Masciovecchio, J. Gabbarini, and M. Vega. "Cystic fibrosis: gene therapy or preventive gene transfer?" Gene Therapy 4, no. 10 (October 1997): 1001–3. http://dx.doi.org/10.1038/sj.gt.3300526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kutsev, S. I., V. L. Izhevskaya, and E. I. Kondratyeva. "Targeted therapy for cystic fibrosis." PULMONOLOGIYA 31, no. 2 (April 11, 2021): 226–36. http://dx.doi.org/10.18093/0869-0189-2021-31-2-226-236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

The basic therapy of cystic fibrosis is currently aimed at slowing down the pathological processes associated with a decrease in the CFTR protein activity (cystic fibrosis transmembrane conductance regulator) in the gastrointestinal tract and the respiratory system. The pancreatic insufficiency is well compensated by replacement therapy with microsphere enzyme preparations and a high-calorie diet rich in proteins and fat. Chronic treatment of cystic fibrosis-related lung disease aims to improve the clearance of the bronchial tree, suppressing chronic bacterial infection and local chronic inflammation. However, no therapy was available to correct the defect in the gene or its product until 2012.The aim was to analyze literature on CFTR modulators, including their efficacy and safety, and assess the potential for developing new modulators to treat cystic fibrosis.Materials. The review included literature data (45 publications) on the use of CFTR modulators and international websites’ data.Results. Since the discovery of the CFTR gene in 1989, more than 2000 mutations or variants of the CFTR gene (hereinafter referred to as genetic variants) have been described. They interfere with the synthesis of the CFTR protein, its transport to the apical membrane of the cell, or disrupt its function as a channel for chloride anions. Although it is currently not possible to completely replace the mutant gene with a normal copy, small molecules have been identified that can modify the mutant CFTR protein and amend its function. The potential therapeutic measures are determined by class of the mutation. In clinical practice, pharmacological modeling of ion transport is currently possible only with the use of CFTR modulators: correctors and potentiators. The review defines these groups of drugs and describes 4 licensed CFTR modulators, including molecules of ivacaftor, lumacaftor, tezacaftor, elexacaftor. The data on the promising emerging next generation modulators and the prospects for the personalized selection of drugs using the assays on intestinal organoids are presented.

39

LEE, Tim W. R., David A. MATTHEWS, and G. Eric BLAIR. "Novel molecular approaches to cystic fibrosis gene therapy." Biochemical Journal 387, no. 1 (March 22, 2005): 1–15. http://dx.doi.org/10.1042/bj20041923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Gene therapy holds promise for the treatment of a range of inherited diseases, such as cystic fibrosis. However, efficient delivery and expression of the therapeutic transgene at levels sufficient to result in phenotypic correction of cystic fibrosis pulmonary disease has proved elusive. There are many reasons for this lack of progress, both macroscopically in terms of airway defence mechanisms and at the molecular level with regard to effective cDNA delivery. This review of approaches to cystic fibrosis gene therapy covers these areas in detail and highlights recent progress in the field. For gene therapy to be effective in patients with cystic fibrosis, the cDNA encoding the cystic fibrosis transmembrane conductance regulator protein must be delivered effectively to the nucleus of the epithelial cells lining the bronchial tree within the lungs. Expression of the transgene must be maintained at adequate levels for the lifetime of the patient, either by repeat dosage of the vector or by targeting airway stem cells. Clinical trials of gene therapy for cystic fibrosis have demonstrated proof of principle, but gene expression has been limited to 30 days at best. Results suggest that viral vectors such as adenovirus and adeno-associated virus are unsuited to repeat dosing, as the immune response reduces the effectiveness of each subsequent dose. Nonviral approaches, such as cationic liposomes, appear more suited to repeat dosing, but have been less effective. Current work regarding non-viral gene delivery is now focused on understanding the mechanisms involved in cell entry, endosomal escape and nuclear import of the transgene. There is now increasing evidence to suggest that additional ligands that facilitate endosomal escape or contain a nuclear localization signal may enhance liposome-mediated gene delivery. Much progress in this area has been informed by advances in our understanding of the mechanisms by which viruses deliver their genomes to the nuclei of host cells.

40

Castellani, Stefano, and Massimo Conese. "Lentiviral Vectors and Cystic Fibrosis Gene Therapy." Viruses 2, no. 2 (January 29, 2010): 395–412. http://dx.doi.org/10.3390/v2020395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Is gene therapy for cystic fibrosis realistic?" Inpharma Weekly &NA;, no. 1137 (May 1998): 6. http://dx.doi.org/10.2165/00128413-199811370-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

DAGANI, RON. "Big step toward cystic fibrosis gene therapy." Chemical & Engineering News 70, no. 3 (January 20, 1992): 6. http://dx.doi.org/10.1021/cen-v070n003.p006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Davies, Jane C. "Gene and cell therapy for cystic fibrosis." Paediatric Respiratory Reviews 7 (January 2006): S163—S165. http://dx.doi.org/10.1016/j.prrv.2006.04.214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Tizzano, Eduardo F., and Manuel Buchwald. "Cystic fibrosis: Beyond the gene to therapy." Journal of Pediatrics 120, no. 3 (March 1992): 337–49. http://dx.doi.org/10.1016/s0022-3476(05)80895-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jaffe, A., A. Bush, D. M. Geddes, and E. W. F. W. Alton. "Prospects for gene therapy in cystic fibrosis." Archives of Disease in Childhood 80, no. 3 (March 1, 1999): 286–89. http://dx.doi.org/10.1136/adc.80.3.286.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Alton, Eric WFW, and Duncan Geddes. "Gene Therapy: The Case for Cystic Fibrosis." Journal of the Royal Society of Medicine 90, no. 31_suppl (December 1997): 43–46. http://dx.doi.org/10.1177/014107689709031s09.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Caplen, Natasha J. "Cystic fibrosis gene therapy trials and tribulations." Trends in Molecular Medicine 7, no. 11 (November 2001): 488. http://dx.doi.org/10.1016/s1471-4914(01)02168-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Davies, Jane C., Duncan M. Geddes, and Eric W. F. W. Alton. "Prospects for gene therapy for cystic fibrosis." Molecular Medicine Today 4, no. 7 (July 1998): 292–99. http://dx.doi.org/10.1016/s1357-4310(98)01265-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Fox, Jeffrey L. "NIHRAC okays gene therapy for cystic fibrosis." Nature Biotechnology 11, no. 1 (January 1993): 29. http://dx.doi.org/10.1038/nbt0193-28b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Griesenbach, U., S. Ferrari, D. M. Geddes, and E. W. F. W. Alton. "Gene Therapy Progress and Prospects: Cystic fibrosis." Gene Therapy 9, no. 20 (October 2002): 1344–50. http://dx.doi.org/10.1038/sj.gt.3301791.

Full text

APA, Harvard, Vancouver, ISO, and other styles